AC
RARE icon

Allstate Corporation’s Ultragenyx Pharmaceutical RARE Stock Holding History

Allstate Corporation’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$657K Buy
+31,378
New +$707K 0.01% 937

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Allstate Corporation's RARE Position: Q1 2026 in Review

Allstate Corporation opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 31,378 shares worth $657K. The stake represents 0.01% of the portfolio and ranks #937 among its holdings.

295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Allstate Corporation held 31,378 shares of Ultragenyx Pharmaceutical worth $657K as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new Allstate Corporation position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.01% of Allstate Corporation's portfolio in Q1 2026, its #937 holding.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Allstate Corporation's 13F filing for Q1 2026, filed 11 May 2026.